Ian Read passed the CEO title on to his hand picked successor Albert Bourla at the beginning of this year, but not before one last big haul of executive compensation. His overall number came down substantially from 2017, largely due to a big drop in the stock option column, but he still scored $19.5 million for 2018 compensation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,